A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma

Trial Profile

A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Buparlisib (Primary) ; Capmatinib (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 12 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2017 This trial was discontinued in Netherlands as per European Clinical Trials Database record.
    • 12 Jan 2017 Trial has been completed in Spain (end date: 2016-12-23), according to the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top